According to filings with the U.S. Securities and Exchange Commission, XOStem Biosciences is raising $1,571,000.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Alex Mcaulay played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About XOStem Biosciences
XOStem is on the leading edge of translational biochemistry, using our Stem Cell expertise to create the next generation treatment for Type 1 Diabetes and produce Engineered Exosomes. Our combination of commercially developed science, partnerships with key scientific institutions, and university validation, enables us to rapidly bring to market novel therapies to tangibly improve peoples lives. More applications utilizing our Stem Cell technology will follow. Our engineered exosome science is bringing to market the next generation of exosomes for regenerative skin care, joint care, and other therapies. Our research, technology and assays encompass the best methods for exosome isolation, purity, and characterization.

To learn more about XOStem Biosciences, visit http://www.xostem.com/

Contact:
Alex Mcaulay, Chief Financial Officer
949-216-3220

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.